Neuregenix is a development stage biotechnology company focused on the development of drugs and biomarkers for the early diagnosis and treatment of acute and chronic neurodegenerative conditions.
Our unique science, stemming from the work of our founding scientists at the University of Birmingham, is focused on developing a range of diagnostic tests and novel therapeutics.
Our current lead technology relates to unique patented sequences of short interfering RNA (siRNA) that have demonstrable RhoA gene silencing activity (termed siRNARhoA), so that signals for neuron death and inhibition of axon growth are suppressed. Pre-clinical studies have shown that the patented siRNARhoA sequences are neuroprotective and significantly enhance nerve regeneration.
Neuregenix is currently seeking key strategic partnerships to help commercialise their siRNA technology for translation to the clinic.